As of May 26
| +0.20 / +4.84%|
The 7 analysts offering 12-month price forecasts for Cardiome Pharma Corp have a median target of 7.00, with a high estimate of 9.50 and a low estimate of 3.50. The median estimate represents a +61.66% increase from the last price of 4.33.
The current consensus among 7 polled investment analysts is to Buy stock in Cardiome Pharma Corp. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.